Key Takeaways:
- An orphan drug treats a rare disease. In the United States, that means a condition affecting fewer than 200,000 people.
- Most rare diseases still have no approved treatment. About 95% of rare diseases lack an FDA-approved therapy, which is why each new approval matters so much to the families waiting for it.
- Approval takes years of advocacy, funding, and persistence. The law that made orphan drugs possible exists because patients and parents pushed for it.
- An approved drug still has to reach the child who needs it. Many orphan drugs require a treatment site with trained clinical staff, pharmacy support, and monitoring.
- Cure 4 The Kids Foundation is a site where orphan drugs can be administered. Children with rare diseases in Nevada, and sometimes from neighboring states, can receive these therapies at C4K’s treatment center in Las Vegas.
An orphan drug is a medication or biologic developed to treat, diagnose, or prevent the progression of a rare disease, defined in the United States as a condition affecting fewer than 200,000 people. The FDA grants orphan drug designation to encourage companies to develop treatments for small patient populations that would otherwise be overlooked.
If your child has been diagnosed with a rare disease, you may hear this term from a physician, a pharmacist, or an insurance company. Here is what it means and why it matters for your family.
Why Are They Called “Orphan” Drugs?
The name comes from the diseases themselves. For decades, conditions that affected small numbers of people were called “orphan diseases” because no one was developing treatments for them. Bringing a drug to market is expensive, and a company could not expect to recover that cost from a few thousand patients.
Families changed that. In the late 1970s and early 1980s, parents and patients organized and pressed Congress to act. The result was the Orphan Drug Act of 1983, a law that researchers describe as a product of grassroots patient advocacy. Before it passed, only 38 drugs for rare diseases had been approved in the United States. The same advocates went on to found the National Organization for Rare Disorders.
How Does a Drug Get Orphan Status?
A company developing a treatment for a rare disease can ask the FDA for orphan drug designation. If the request is granted, the company qualifies for incentives that make the work more financially realistic:
- Tax credits for qualified clinical trials
- Exemption from certain FDA fees
- The potential for seven years of market exclusivity after approval
Designation and approval are two separate steps. Designation happens during development. To be approved, an orphan drug goes through the same scientific review for safety and effectiveness as any other medication.
Why Is an Orphan Drug Approval Such a Big Deal?
More than 10,000 rare diseases affect over 30 million Americans, and nearly 70% of them begin in childhood. About 95% have no FDA-approved treatment. For most families, a rare diagnosis comes with a care plan focused on managing symptoms, because nothing exists yet to treat the disease itself.
Every approval changes that for one group of patients, and none of them happen quickly. Clinical trials are hard to run when only a few hundred people in the country have a condition. Patient organizations often raise research money themselves, build registries of affected families, and spend years making their case to researchers, companies, and lawmakers. An orphan drug approval usually represents a decade or more of that work.
The pace has picked up. In 2025, half of the FDA’s novel drug approvals (23 of 46) had orphan drug designation, including new treatments for hemophilia and Barth syndrome. In February 2026, Congress reauthorized the Rare Pediatric Disease Priority Review Voucher program through September 2029, renewing an incentive aimed specifically at treatments for children.
Why Are Orphan Drugs So Expensive?
Development costs are spread across a small number of patients, so the price per patient is high. The median annual list price for medicines launched in 2024 was more than $350,000, and rare disease therapies ran higher.
List price is rarely what a family pays. Insurance coverage, prior authorization, manufacturer assistance programs, and nonprofit foundations all play a part, and sorting through them takes time and expertise. Coverage varies from plan to plan, which is one reason the treatment site a family works with matters.
How Are Orphan Drugs Given?
Some orphan drugs are pills or liquids taken at home. Many others are infusions or injections that need to be given in a clinical setting by nurses trained in that specific therapy. These drugs may require special storage and preparation, careful dosing by weight, and monitoring during and after each visit.
This means an approved drug is only useful to a child if there is a place within reach that can administer it. Where a family lives still shapes their options. NORD’s most recent State Report Card found that access to rare disease care continues to depend heavily on geography, and an earlier NORD survey found that nearly 40% of rare disease patients traveled more than 60 miles for medical care.
Where Can Children in Nevada Receive Orphan Drugs?
Cure 4 The Kids Foundation is Nevada’s only dedicated outpatient pediatric cancer and rare disease treatment center, and it is a site where orphan drugs can be administered. Our infusion center, on-site pharmacy, and pediatric specialists in hematology, oncology, and rheumatology are in one location in Las Vegas.
For families in Southern Nevada, that can mean receiving a specialized therapy close to home instead of traveling to another state for every dose. Our reach also extends past the state line. Patients from many other states are referred to us for treatment.
When a physician prescribes an orphan drug, our team works with the family, the insurer, and the manufacturer to look for a way to bring that treatment to the child. These cases are often complicated, and we take them on one at a time.
What Should You Do If Your Child Needs an Orphan Drug?
Start with your child’s rare disease specialist. Ask whether an FDA-approved treatment exists for the diagnosis, whether any clinical trials are open, and where the treatment can be given.
If you are a parent or a referring provider and want to know whether a therapy can be administered at Cure 4 The Kids Foundation, call us at (702) 732-1493. You can also visit our referring providers page to learn more about our specialists.
Frequently Asked Questions About Orphan Drugs
What is an orphan drug in simple terms?
An orphan drug is a medicine made to treat a rare disease. In the United States, a disease is considered rare when it affects fewer than 200,000 people.
Are orphan drugs FDA approved?
Some are, and some are still in development. Orphan drug designation is a status granted while a drug is being studied. The drug must still pass the FDA’s full review for safety and effectiveness before it can be prescribed.
How many rare diseases have an approved treatment?
About 5%. Roughly 95% of the more than 10,000 known rare diseases have no FDA-approved therapy.
Why do orphan drugs cost so much?
The cost of research and development is divided among a small number of patients. Insurance, manufacturer assistance programs, and nonprofit support often reduce what families pay.
Can my child receive an orphan drug at Cure 4 The Kids Foundation?
Cure 4 The Kids Foundation is a site where orphan drugs can be administered. Whether a specific therapy is available depends on your child’s diagnosis and treatment plan, so the best first step is to call us or ask your child’s physician to send a referral.
Do I need a referral to be seen at Cure 4 The Kids Foundation?
Yes. Families are referred by a provider. Call 702-732-3330 to learn more about the referral process.
About the Author: Annette Logan-Parker brings over 30 years of experience in pediatric oncology to her role as Founder and Chief Advocacy & Innovation Officer at Cure 4 The Kids Foundation. She has dedicated her career to improving outcomes for children with cancer and ensuring equitable access to cutting-edge treatments for all families.
